Divi's Laboratories バランスシートの健全性

財務の健全性基準チェック /66

Divi's Laboratoriesの総株主資本は₹137.2B 、総負債は₹50.0Mで、負債比率は0.04%となります。総資産と総負債はそれぞれ₹155.9Bと₹18.7Bです。 Divi's Laboratoriesの EBIT は₹21.8Bで、利息カバレッジ比率-7.3です。現金および短期投資は₹36.0Bです。

主要情報

0.04%

負債資本比率

₹50.00m

負債

インタレスト・カバレッジ・レシオ	-7.3x
現金	₹36.02b
エクイティ	₹137.17b
負債合計	₹18.69b
総資産	₹155.86b

財務の健全性に関する最新情報

更新なし

Recent updates

Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)

Sep 06

Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

Aug 06

The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Jul 19

Shareholders Should Be Pleased With Divi's Laboratories Limited's (NSE:DIVISLAB) Price

Apr 19

Divi's Laboratories' (NSE:DIVISLAB) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 21

Divi's Laboratories (NSE:DIVISLAB) Will Pay A Larger Dividend Than Last Year At ₹30.00

Jul 07

Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Might Deserve Your Attention Today

Jul 03

Does Divi's Laboratories (NSE:DIVISLAB) Deserve A Spot On Your Watchlist?

Apr 03

Should You Be Adding Divi's Laboratories (NSE:DIVISLAB) To Your Watchlist Today?

Dec 23

With EPS Growth And More, Divi's Laboratories (NSE:DIVISLAB) Is Interesting

Sep 02

財務状況分析

短期負債: DIVISLABの短期資産 ( ₹93.4B ) が短期負債 ( ₹12.9B ) を超えています。

長期負債: DIVISLABの短期資産 ( ₹93.4B ) が長期負債 ( ₹5.8B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: DIVISLAB総負債よりも多くの現金を保有しています。

負債の削減: DIVISLABの負債対資本比率は、過去 5 年間で0.2%から0.04%に減少しました。

債務返済能力: DIVISLABの負債は営業キャッシュフローによって十分にカバーされています ( 32960% )。

インタレストカバレッジ: DIVISLAB支払う利息よりも稼ぐ利息の方が多いので、利息支払いの補償は問題になりません。

Divi's Laboratories バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Recent updates

Price target increased by 7.7% to ₹4,881

Second quarter 2025 earnings released: EPS: ₹19.20 (vs ₹13.11 in 2Q 2024)

Divi's Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024

Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)

Chief Technologist - PDSC recently sold ₹9.8m worth of stock

Insider recently sold ₹59m worth of stock

Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2024

Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

Price target increased by 9.6% to ₹4,300

Upcoming dividend of ₹30.00 per share

Divi's Laboratories Limited to Report Q1, 2025 Results on Aug 03, 2024

The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Divi's Laboratories Limited Announces Board and Committee Changes

Insider recently sold ₹46m worth of stock

Insider recently sold ₹238m worth of stock

Dividend of ₹30.00 announced

Price target increased by 11% to ₹3,806

Divi's Laboratories Limited Recommends A Final Dividend for the Financial Year 2023-24

Divi's Laboratories Limited to Report Q4, 2024 Results on May 25, 2024

Shareholders Should Be Pleased With Divi's Laboratories Limited's (NSE:DIVISLAB) Price

Divi's Laboratories Limited Approves Appointment of Dr. S. Devendra Rao as Whole-Time Director (Manufacturing)

Insider recently sold ₹24m worth of stock

Chief Technologist recently sold ₹56m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Divi's Laboratories Limited to Report Q3, 2024 Results on Feb 10, 2024

Insider recently sold ₹59m worth of stock

Divi's Laboratories Limited (NSE:DIVISLAB) Not Flying Under The Radar

Non-Executive Independent Director recently sold ₹1.4m worth of stock

Consensus EPS estimates fall by 10%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Divi's Laboratories Limited to Report Q2, 2024 Results on Nov 06, 2023

Insider recently sold ₹3.3m worth of stock

Chief Technologist recently sold ₹2.9m worth of stock

Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2023

Divi's Laboratories Limited Informs Resignations of Directors

Price target increased by 7.3% to ₹3,325

New minor risk - Profit margin trend

Insufficient new directors

Divi's Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of ₹30.00 per share at 0.8% yield

Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00

Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00

New minor risk - Insider selling

Divi's Laboratories (NSE:DIVISLAB) Has Announced A Dividend Of ₹30.00

Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023

Insider recently sold ₹3.4m worth of stock

Divi's Laboratories Limited Recommends a Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹68.69 (vs ₹112 in FY 2022)

Divi's Laboratories Limited to Report Q4, 2023 Results on May 20, 2023

Insider recently sold ₹2.0m worth of stock

Global Quality Head recently sold ₹2.3m worth of stock

Global Quality Head recently sold ₹2.8m worth of stock

Global Quality Head recently sold ₹28m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%

Divi's Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023

Board Member recently sold ₹10m worth of stock

MD & Executive Director recently sold ₹1.0m worth of stock

Insider recently sold ₹1.7m worth of stock

Insider recently sold ₹1.2m worth of stock

Consensus EPS estimates fall by 12%

Price target decreased to ₹3,582

Price target decreased to ₹3,685

Price target decreased to ₹3,685

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Now The Time To Put Divi's Laboratories (NSE:DIVISLAB) On Your Watchlist?

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹3.7m worth of stock

Upcoming dividend of ₹30.00 per share

Divi's Laboratories (NSE:DIVISLAB) Is Increasing Its Dividend To ₹30.00

Divi's Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Divi's Laboratories' (NSE:DIVISLAB) Shareholders Will Receive A Bigger Dividend Than Last Year

財務の健全性基準チェック /66